NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Definium Therapeutics, Inc. (DFTX) Stock Analysis

Definium Therapeutics, Inc. (DFTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DFTX

$35.49

+$0.40 (+1.14%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DFTX with… →

DFTX Key Statistics

As of Oct 21, 2026
Trading
Open
$35.11
Previous Close
$35.09
Day's Range
35.04–36.34
52-Week Range
10.47–49.70
Volume
2.91M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.19
Valuation
Market Cap
$4.77B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.43
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$183.79M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
134.37M
1-Year Return
+180.78%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.14M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DFTX closed at $35.49, +180.78% over 1 year.

Definium Therapeutics, Inc. (DFTX) has a market capitalization of $4.77B.

In fiscal 2025, DFTX reported revenue of $0.00.

DFTX Stock Return by Calendar Year

Definium Therapeutics, Inc. (DFTX) return since Nov 2016: what $10,000 became

1 year
$10,000 $28,078
+180.78%
5 years
$10,000 $9,540
−4.60%
Since Nov 2016
$10,000 $105,156
+951.56%

If you had invested $10,000 in Definium Therapeutics, Inc. (DFTX) at the close on November 15, 2016, the earliest close on record here, it would have been worth $105,156 at the close on October 21, 2026: +951.56% in total, +26.74% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+165.05%
2025+92.39%
2024+90.16%
2023+66.36%
2022−89.37%
2021−54.75%
2020+5,346.43%
2019+27.27%
2018−85.19%
2017−45.90%
2016 (partial year)+144.00%

As of October 21, 2026.

DFTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$183.79M—
2024$0.00−$108.68M—
2023$0.00−$95.73M—
2022$0.00−$56.80M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$166.31M−$183.79M—
2024$0.00—−$103.92M−$108.68M—
2023$0.00—−$93.87M−$95.73M—
2022$0.00—−$66.33M−$56.80M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Definium Therapeutics, Inc. (DFTX) is capitalised at $4.77B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 105 employees.

The most recent close on file for DFTX is $35.49, dated October 21, 2026. That is +$0.40 (+1.14%) against the previous close. Over the past 52 weeks the price has ranged from $10.47 to $49.70. The latest close sits 239.13% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $183.79M. Trailing earnings per share are −3.43.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is +180.78%. Across 5 years the annualized return works out at −0.94%. The reported beta is 2.19. Daily returns over the trailing 9 years annualize to a volatility of 1,589.51%.

Growth & Income

The record shows no dividend for DFTX.

So far in 2026 the total return is +165.05%. The strongest complete calendar year on file is 2020 at +5,346.43%; the weakest is 2022 at −89.37%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Definium Therapeutics, Inc. (DFTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Definium Therapeutics, Inc. DFTX $4.77B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Definium Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Visit website →